EUVIMEDOpdag EUVIMED
Open access

Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.

Shailesh N Khatri, Safiyah Sadek, Percell T Kendrick, Emma O Bondy iD, Mei Hong, Sally Pauss, Dan Luo, Thomas E Prisinzano, Kelly E Dunn, Julie A Marusich iD, Joshua S Beckmann, Terry D Hinds and 1 more

Experimental and Clinical Psychopharmacology · 2024-04 · 32 (2) · 150-157

DOI: 10.1037/pha0000670 ↗

At a glance

Journal article in Experimental and Clinical Psychopharmacology, 2024-04. Written by Shailesh N Khatri and 12 co-authors. Institution: Department of Pharmacology and Nutritional Sciences, University of Kentucky. Major MEDLINE topics: Substance Withdrawal Syndrome, Drug Overdose. Cited 40 times so far (Crossref). The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Prescription and illicit opioid use are a public health crisis, with the landscape shifting to fentanyl use. Since fentanyl is 100-fold more potent than morphine, its use is associated with a higher risk of fatal overdose that can be remediated through naloxone (Narcan) administration. However, recent reports indicate that xylazine, an anesthetic, is increasingly detected in accidental fentanyl overdose deaths. Anecdotal reports suggest that xylazine may prolong the fentanyl "high," alter the onset of fentanyl withdrawal, and increase resistance to naloxone-induced reversal of overdose. To date, no preclinical studies have evaluated the impacts of xylazine on fentanyl self-administration (SA; 2.5 μg/kg/infusion) or withdrawal to our knowledge. We established a rat model of xylazine/fentanyl co-SA and withdrawal and evaluated outcomes as a function of biological sex. When administered alone, chronic xylazine (2.5 mg/kg, intraperitoneal) induced unique sex-specific withdrawal symptomatology, whereby females showed delayed onset of signs and a possible enhancement of sensitivity to the motor-suppressing effects of xylazine. Xylazine reduced fentanyl consumption in both male and female rats regardless of whether it was experimenter-administered or added to the intravenous fentanyl product (0.05, 0.10, and 0.5 mg/kg/infusion) when compared to fentanyl SA alone. Interestingly, this effect was dose-dependent when self-administered intravenously. Naloxone (0.1 mg/kg, subcutaneous injection) did not increase somatic signs of fentanyl withdrawal, regardless of the inclusion of xylazine in the fentanyl infusion in either sex; however, somatic signs of withdrawal were higher across time points in females after xylazine/fentanyl co-SA regardless of naloxone exposure as compared to females following fentanyl SA alone. Together, these results indicate that xylazine/fentanyl co-SA dose-dependently suppressed fentanyl intake in both sexes and induced a unique withdrawal syndrome in females that was not altered by acute naloxone treatment. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

Subjects

MeSH terms (MEDLINE)

Substance Withdrawal SyndromeDrug OverdoseRatsMaleFemaleAnimalsNaloxoneFentanylXylazineNarcotic AntagonistsMorphineAnalgesics, Opioid

Substances

NaloxoneFentanylXylazineNarcotic AntagonistsMorphineAnalgesics, Opioid

Authors and institutions

  • Department of Pharmacology and Nutritional Sciences, University of Kentucky.
  • Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky.
  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University.
  • Center for Drug Discovery, RTI International.
  • Department of Psychology, University of Kentucky.

ORCID profiles: Emma O Bondy, Julie A Marusich, Cassandra D Gipson

Funding

  • NIDA NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Kentucky Medical Services Foundation

Cite

APA

Khatri, S. N., Sadek, S., Kendrick, P. T., Bondy, E. O., Hong, M., Pauss, S., Luo, D., Prisinzano, T. E., Dunn, K. E., Marusich, J. A., Beckmann, J. S., Hinds, T. D., & Gipson, C. D. (2024). Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. Experimental and Clinical Psychopharmacology, 32(2), 150-157. https://doi.org/10.1037/pha0000670

Vancouver

Khatri SN, Sadek S, Kendrick PT, Bondy EO, Hong M, Pauss S, et al. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. Experimental and Clinical Psychopharmacology. 2024;32(2):150-157. doi:10.1037/pha0000670

BibTeX
@article{Khatri2024,
  author = {Khatri, Shailesh N and Sadek, Safiyah and Kendrick, Percell T and Bondy, Emma O and Hong, Mei and Pauss, Sally and Luo, Dan and Prisinzano, Thomas E and Dunn, Kelly E and Marusich, Julie A and Beckmann, Joshua S and Hinds, Terry D and Gipson, Cassandra D},
  title = {Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats},
  journal = {Experimental and Clinical Psychopharmacology},
  year = {2024},
  volume = {32},
  number = {2},
  pages = {150--157},
  doi = {10.1037/pha0000670}
}
Start for free →